Showing results (121-130 of 131) with videos related to
Sort By:
Pageof 14
The Journal of Clinical Investigation|October 24, 2018
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunityHui-Ming Chen, William van der Touw, Yuan Shuo Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|February 26, 2014
Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibilityHui Jin, Noriko Arase, Kouyuki Hirayasu, et al.Cell Reports|December 30, 2021
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistanceIzumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 30, 2026
Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV InfectionFlorian Meurisse, Sixtine Coindre, Anne Wijkhuisen, et al.Cancer Research|June 5, 2012
Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesisShoichi Ihara, Hiroshi Kida, Hisashi Arase, et al.Cell|September 14, 2024
Neoself-antigens are the primary target for autoreactive T cells in human lupusShunsuke Mori, Masako Kohyama, Yoshiaki Yasumizu, et al.Current Research in Translational Medicine|April 30, 2022
Preclinical study of a DNA vaccine targeting SARS-CoV-2Hiroki Hayashi, Jiao Sun, Yuka Yanagida, et al.The Journal of Experimental Medicine|October 14, 2021
Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patientsXiuyuan Lu, Yuki Hosono, Masamichi Nagae, et al.Science Translational Medicine|August 30, 2023
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical modelsEmiko Urano, Yumi Itoh, Tatsuya Suzuki, et al.Cell|June 17, 2021
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodiesYafei Liu, Wai Tuck Soh, Jun-Ichi Kishikawa, et al.Pageof 14